LETTER TO THE EDITOR
Chemotherapy and atrial fibrillation
Yusuf Ziya Şener,
Corresponding Author
Yusuf Ziya Şener
Hacettepe University, Cardiology Department, Hacettepe University Faculty of Medicine, Sohhıye, Ankara, 06532 Turkey
Correspondence
Yusuf Ziya Şener, Hacettepe University, Cardiology Department, Hacettepe University Faculty of Medicine, Sohhıye, Ankara, 06532, Turkey
Email: [email protected]
Search for more papers by this author
Yusuf Ziya Şener,
Corresponding Author
Yusuf Ziya Şener
Hacettepe University, Cardiology Department, Hacettepe University Faculty of Medicine, Sohhıye, Ankara, 06532 Turkey
Correspondence
Yusuf Ziya Şener, Hacettepe University, Cardiology Department, Hacettepe University Faculty of Medicine, Sohhıye, Ankara, 06532, Turkey
Email: [email protected]
Search for more papers by this author
First published: 18 November 2020
No abstract is available for this article.
REFERENCES
- 1Ezad S, Khan AA, Cheema H, et al. Ibrutinib-related atrial fibrillation: a single-center Australian experience. Asia Pac J Clin Oncol. 2019; 15(5): e187-e190.
- 2Eichhorst B, Robak T, Montserrat P, et al. Chronic lymphocytic leukaemia: eSMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26(Suppl 5): v78-v84.
- 3Newbery G, Lima NA, Gurgel LA, et al. Persistent heart failure following melphalan and fludarabine conditioning. J Cardiol Cases. 2019; 20(3): 88-91.
- 4Kurauchi K, Nishikawa T, Miyahara E, Okamoto Y, Kawano Y. Role of metabolites of cyclophosphamide in cardiotoxicity. BMC Res Notes. 2017; 10(1): 406.
- 5Cheungpasitporn W, Kopecky SL, Specks U, Bharucha K, Fervenza FC. Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. J Renal Inj Prev. 2016; 6(1): 18-25.
